Mineralys Therapeutics Inc (MLYS)

Jan 20, 2025

Mineralys Therapeutics Appoints Dr. Alexander Gold to Board Amid Hypertension Drug Development - MSN

Jan 20, 2025

Jan 19, 2025

Mineralys Therapeutics: Lorundrostat Is Worth A Shot In 2025 For Hypertension - Seeking Alpha

Jan 19, 2025

Jan 18, 2025

Barclays PLC Grows Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - MarketBeat

Jan 18, 2025

Jan 18, 2025

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock Holdings Boosted by Barclays PLC - Defense World

Jan 18, 2025

Jan 16, 2025

When (MLYS) Moves Investors should Listen - Stock Traders Daily

Jan 16, 2025

Jan 16, 2025

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CFO Adam Scott Levy Sells 10,757 Shares - MarketBeat

Jan 16, 2025

Jan 15, 2025

Insider Sell: CEO Jon Congleton Sells Shares of Mineralys Therap - GuruFocus.com

Jan 15, 2025

Jan 15, 2025

Insider Sell: Adam Levy Sells Shares of Mineralys Therapeutics I - GuruFocus.com

Jan 15, 2025

Jan 15, 2025

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) CEO Sells $166,096.98 in Stock - MarketBeat

Jan 15, 2025

Jan 15, 2025

Mineralys Therapeutics CEO Jon Congleton sells $166,082 in stock By Investing.com - Investing.com Nigeria

Jan 15, 2025

Jan 15, 2025

Mineralys therapeutics CFO Adam Levy sells $97,863 in stock By Investing.com - Investing.com Australia

Jan 15, 2025

Jan 15, 2025

Mineralys Therapeutics CEO Jon Congleton sells $166,082 in stock - Investing.com India

Jan 15, 2025

Jan 15, 2025

Mineralys therapeutics CFO Adam Levy sells $97,863 in stock - Investing.com

Jan 15, 2025

Jan 15, 2025

Overcoming Barriers in Obesity and Hypertension Management: Practical Strategies for Physicians - Patient Care Online

Jan 15, 2025

Jan 14, 2025

Mineralys Therapeutics Receives FDA Clearance for Phase 2 Trial of Lorundrostat in Treating Sleep Apnea and Hypertension - MSN

Jan 14, 2025

Jan 13, 2025

Jane Street Group LLC Has $192,000 Holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World

Jan 13, 2025

Jan 11, 2025

Passage Bio Reports Promising Data in Trial for Frontotemporal Dementia Treatment - MyChesCo

Jan 11, 2025

Jan 11, 2025

Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with HypertensionRADNOR, PA – January 8, 2025 – Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company f - Defense World

Jan 11, 2025

Jan 09, 2025

Mineralys Therapeutics Advances Lorundrostat to Phase 2 Trials - Yahoo Finance

Jan 09, 2025

Jan 09, 2025

Mineralys Therapeutics gets FDA nod for sleep apnea drug trial By Investing.com - Investing.com Nigeria

Jan 09, 2025

Jan 08, 2025

Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat - Diagnostic and Interventional Cardiology

Jan 08, 2025

Jan 08, 2025

Mineralys Therapeutics (NASDAQ:MLYS) Shares Down 9.6%Here's Why - MarketBeat

Jan 08, 2025

Jan 08, 2025

Mineralys Therapeutics : Corporate Overview January 2025 - Marketscreener.com

Jan 08, 2025

Jan 08, 2025

Mineralys Therapeutics Announces Phase 2 Clinical Trial of - GlobeNewswire

Jan 08, 2025

Jan 08, 2025

Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat for Obstructive Sleep Apnea in Patients with Hypertension - Marketscreener.com

Jan 08, 2025

Jan 08, 2025

Mineralys Therapeutics gets FDA nod for sleep apnea drug trial - Investing.com

Jan 08, 2025

Jan 08, 2025

Mineralys Gets FDA Green Light for Sleep Apnea Drug Trial, Targets 54M Patient Market - StockTitan

Jan 08, 2025

Jan 06, 2025

Objective long/short (MLYS) Report - Stock Traders Daily

Jan 06, 2025

Jan 03, 2025

Neumora shares sink following Phase III flop in MDD - MSN

Jan 03, 2025

Jan 03, 2025

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Bought by Geode Capital Management LLC - Defense World

Jan 03, 2025

Jan 03, 2025

Barclays PLC Buys 28,208 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World

Jan 03, 2025

Dec 29, 2024

State Street Corp Grows Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World

Dec 29, 2024

Dec 29, 2024

Mineralys Therapeutics (NASDAQ:MLYS) Trading 4% Higher – Still a Buy? - Defense World

Dec 29, 2024

Dec 27, 2024

Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 4%Here's What Happened - MarketBeat

Dec 27, 2024

Dec 26, 2024

Mineralys Therapeutics (NASDAQ:MLYS) Trading Down 4.1%Here's Why - MarketBeat

Dec 26, 2024

Dec 26, 2024

(MLYS) Trading Report - Stock Traders Daily

Dec 26, 2024

Dec 22, 2024

Mineralys Therapeutics (NASDAQ:MLYS) Trading 3% Higher – Still a Buy? - Defense World

Dec 22, 2024

Dec 20, 2024

Mineralys Therapeutics (NASDAQ:MLYS) Trading 3% HigherWhat's Next? - MarketBeat

Dec 20, 2024

Dec 20, 2024

Franklin Resources Inc. Boosts Stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - MarketBeat

Dec 20, 2024

Dec 20, 2024

Wellington Management Group LLP Invests $775,000 in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - MarketBeat

Dec 20, 2024

Dec 19, 2024

MLYS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Mineralys Therapeutics, Inc. and Encourages Investors to Contact the Firm! - The Eastern Progress Online

Dec 19, 2024

Dec 18, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mineralys Therapeutics, Inc.MLYS - The Eastern Progress Online

Dec 18, 2024

Dec 18, 2024

Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Down 3.8%Here's Why - MarketBeat

Dec 18, 2024

Dec 16, 2024

Charles Schwab Investment Management Inc. Buys 9,664 Shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS) - Defense World

Dec 16, 2024

Dec 14, 2024

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Shares Bought by Fmr LLC - Defense World

Dec 14, 2024

Dec 12, 2024

Prelude Therapeutics Shares Promising Data for CDK9 Inhibitor PRT2527 - MyChesCo

Dec 12, 2024

Dec 11, 2024

Mineralys therapeutics CMO sells shares worth $75,398 By Investing.com - Investing.com Nigeria

Dec 11, 2024